Randomized phase I/II clinical trial of a melanoma helper peptide vaccine with or without systemic agonistic anti-CD27 antibody (varlilumab)

Key Points

• This research aims to determine the safety and effectiveness of a melanoma vaccine with and without an anti-CD27 antibody.
• Conducted a randomized phase I/II clinical trial
• Administered melanoma helper peptide vaccine
• Included patients receiving either with or without varlilumab
• Monitored for toxicity and immunogenicity outcomes
• No combined treatment toxicities were observed
• Immunogenicity durability remained similar in both treatment arms
• CD4+ T cell depletion may have reduced the expected benefits from vaccination
• Induction of memory responses was noted, indicating potential for further research